Sony DADC BioSciences and TSMC Receive AACC Award
|
By LabMedica International staff writers Posted on 29 Jul 2014 |
The American Association for Clinical Chemistry (AACC) presented Sony DADC BioSciences and Taiwan Semiconductor Manufacturing Co. Ltd. (TSMC; Hsinchu, Taiwan) with the AACC Industry Division Award.
The winning abstract, “Versatile Electrical Platform for Accelerated Development and Commercialization of In-Vitro Diagnostic Assays,” describes a process to integrate a novel silicon biosensor into a microfluidic chip, which has the potential to enable customers to design cost-effective, mass-fabricated Point-of-Care (POC) devices with better sensitivity and higher robustness than other available solutions.
The award is selected by a committee formed by the Chair of the AACC Industry Division, and given to research deemed to present a significant contribution to the in vitro diagnostic industry in management, regulatory affairs, or improved patient care, through a new or improved medical device.
The award-winning research combines Sony DADC BioSciences’ position in original equipment manufacturer (OEM) manufacturing of smart polymer-based consumables and TSMC’s deep expertise in silicon biosensor manufacturing. It aims to overcome a major hurdle for further development of point-of-care (POC) devices by improving material compatibility and positional alignment between silicon and plastics. Both partners have applied best-in-class silicon and plastic material-sciences to create a demonstrator for a novel hybrid design. The novelty of the silicon biosensor manufactured by TSMC is complemented by solid-state bonding of silicon to microstructured plastics developed by Sony DADC BioSciences.
Closing the gap between macro and micro interfaces allows simple and robust instrument interfaces, which serve the needs of POC environments. Both companies together will engage in discussions with diagnostic industry leaders as early adopters of the new manufacturing techniques to integrate biosensors.
Dr. Christoph Mauracher, senior vice president at Sony DADC BioSciences Sony DADC BioSciences notes, “Sony DADC BioSciences has enjoyed the cooperative development with TSMC to create a novel silicon-plastic fluidic interface which enables simple integration of microfluidic functionalities like filters, mixers, valves and pumps while ensuring a robust sample input and waste management.”
Related Links:
Sony DADC BioSciences
TSMC
The winning abstract, “Versatile Electrical Platform for Accelerated Development and Commercialization of In-Vitro Diagnostic Assays,” describes a process to integrate a novel silicon biosensor into a microfluidic chip, which has the potential to enable customers to design cost-effective, mass-fabricated Point-of-Care (POC) devices with better sensitivity and higher robustness than other available solutions.
The award is selected by a committee formed by the Chair of the AACC Industry Division, and given to research deemed to present a significant contribution to the in vitro diagnostic industry in management, regulatory affairs, or improved patient care, through a new or improved medical device.
The award-winning research combines Sony DADC BioSciences’ position in original equipment manufacturer (OEM) manufacturing of smart polymer-based consumables and TSMC’s deep expertise in silicon biosensor manufacturing. It aims to overcome a major hurdle for further development of point-of-care (POC) devices by improving material compatibility and positional alignment between silicon and plastics. Both partners have applied best-in-class silicon and plastic material-sciences to create a demonstrator for a novel hybrid design. The novelty of the silicon biosensor manufactured by TSMC is complemented by solid-state bonding of silicon to microstructured plastics developed by Sony DADC BioSciences.
Closing the gap between macro and micro interfaces allows simple and robust instrument interfaces, which serve the needs of POC environments. Both companies together will engage in discussions with diagnostic industry leaders as early adopters of the new manufacturing techniques to integrate biosensors.
Dr. Christoph Mauracher, senior vice president at Sony DADC BioSciences Sony DADC BioSciences notes, “Sony DADC BioSciences has enjoyed the cooperative development with TSMC to create a novel silicon-plastic fluidic interface which enables simple integration of microfluidic functionalities like filters, mixers, valves and pumps while ensuring a robust sample input and waste management.”
Related Links:
Sony DADC BioSciences
TSMC
Latest AACC 2014 News
- Corgenix Diagnostic Ebola Test Research Earns Abstract Award
- Atomo's Blood Test Unveiled at 2014 AACC; Takes Top Award in NY
- Roche Partners with Customers, Redefines Laboratory Value
- Abbott Showcases Innovations, Helps Labs Solve Health Care Challenges
- Oncolab Exhibits Pioneering AMAS Cancer Test at AACC
- Thermo Fisher Scientific Showcases Expanded Offering for Clinical Laboratory
- Major Advances in Medical Studies Highlighted at AACC 2014
- Wheaton Offers Unique Solutions for the Clinical Market
- Seegene Reveals New Real-Time PCR at AACC 2014
- AACC Debuts Refreshed Brand Identity
- Mobile Health, Big Data, Antimicrobial Resistance Central to 2014 Meeting
- EKF Highlights Growing Product Portfolio at AACC 2014 Meeting
Channels
Clinical Chemistry
view channel
Blood Test Detects More High-Risk Prostate Cancers Than PSA
Prostate cancer is one of the most common malignancies in men, and screening often struggles to distinguish indolent tumors from clinically significant disease. Prostate-specific antigen (PSA) testing... Read more
Rapid Blood Test Aids Diagnosis of Acute Ischemic Stroke
Rapid and accurate differentiation of stroke types remains a persistent challenge in emergency medicine, particularly because early imaging can miss ischemic events that require time-sensitive intervention.... Read moreMolecular Diagnostics
view channel
Genomic Test Guides Taxane-Based Chemotherapy Selection in Breast Cancer
Selecting adjuvant chemotherapy for hormone receptor–positive, HER2-negative (HR+/HER2−) breast cancer remains challenging because current genomic assays mainly estimate recurrence risk rather than predict... Read more
RNA Blood Test May Enable Earlier Alzheimer’s Disease Diagnosis
Alzheimer’s disease affects an estimated 55 million people worldwide and remains difficult to diagnose at an early stage. Diagnostic workups can be complicated by symptom overlap with other conditions,... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
Conventional cytotoxicity assays often average responses across thousands of cells, obscuring how individual immune cells engage and kill tumor cells. For immunotherapy evaluation, the precise sequence... Read more
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreMicrobiology
view channel
Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read morePathology
view channel
Study Highlights Biomarker Testing Delays in Lung Cancer Care
Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read more
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Partnership Aims to Improve Transplant Monitoring Across Care Continuum
Allograft rejection and chronic graft dysfunction remain major challenges in solid organ transplantation, requiring careful immunologic matching and long-term surveillance. Fragmented pre- and post-transplant... Read more
QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more









